Li Zifeng, Yang Luhuan, Xi Zuyang, Yi Wen, Fu Yuanzhi, Chang Caiyun, Lei Yunhong
Department of Traditional Chinese Medicine, The First College of Clinical Medical Science, Three Gorges University/Yichang Central People's Hospital, Yichang City, Hubei Province, China.
Academic Research Center, Yichang Famous Doctor Studio, Yichang City, Hubei Province, China.
Medicine (Baltimore). 2025 Sep 5;104(36):e44396. doi: 10.1097/MD.0000000000044396.
Previous studies have reported inconsistent findings regarding the diagnostic role of Krebs Von den Lungen-6 (KL-6) in dermatomyositis/polymyositis-associated interstitial lung disease (PM/DM-ILD) and its correlation with disease severity. This meta-analysis aimed to evaluate the diagnostic efficacy of serum KL-6 in detecting DM/PM-ILD and its association with pulmonary function.
In April 2023, we systematically searched PubMed, Web of Science, Cochrane Library, CNKI, Wan Fang, and VIP databases to identify studies investigating the association of KL-6 with DM/PM-ILD. Two authors independently screened the literature and assessed the risk of bias for included studies. Data synthesis and analysis were performed using SPSS 20.0 (Chicago), Excel, and Stata 15.0 software, with effect sizes calculated using standard mean differences and 95% confidence intervals (CIs). Diagnostic accuracy was assessed using sensitivity, specificity, and summary receiver operating characteristic curve analysis. This meta-analysis was registered in INPLASY. https://inplasy.com/inplasy-2022-6-0106/.
Of the 334 studies retrieved, 9 were included in this meta-analysis. The analysis showed that serum KL-6 levels were significantly higher in DM/PM patients with ILD compared to those without ILD (WMD = 757.15, 95% CI: 558.88-885.41, P <.05). Serum KL-6 demonstrated a sensitivity of 0.82 (95% CI: 0.73-0.89), specificity of 0.90 (95% CI: 0.77-0.96), and an area under the combined summary receiver operating characteristic curve of 0.91 (95% CI: 0.89-0.94). Correlation analyses revealed significant associations between KL-6 levels and various pulmonary function parameters (all P <.05).
Serum KL-6 shows promise as a diagnostic marker for DM/PM-ILD and is closely associated with disease severity.
先前的研究报告了关于克雷布斯-冯-登-卢肯斯6（KL-6）在皮肌炎/多发性肌炎相关间质性肺病（PM/DM-ILD）中的诊断作用及其与疾病严重程度的相关性的不一致结果。本荟萃分析旨在评估血清KL-6在检测DM/PM-ILD中的诊断效能及其与肺功能的关联。
2023年4月，我们系统检索了PubMed、Web of Science、Cochrane图书馆、中国知网、万方和维普数据库，以识别研究KL-6与DM/PM-ILD关联的研究。两位作者独立筛选文献并评估纳入研究的偏倚风险。使用SPSS 20.0（芝加哥）、Excel和Stata 15.0软件进行数据合成和分析，效应量使用标准平均差和95%置信区间（CI）计算。使用敏感性、特异性和汇总接受者操作特征曲线分析评估诊断准确性。本荟萃分析已在INPLASY注册。https://inplasy.com/inplasy-2022-6-0106/。
在检索到的334项研究中，9项被纳入本荟萃分析。分析表明，与无ILD的DM/PM患者相比，有ILD的DM/PM患者血清KL-6水平显著更高（加权均数差=757.15，95%CI：558.88-885.41，P<0.05）。血清KL-6的敏感性为0.82（95%CI：0.73-0.89），特异性为0.90（95%CI：0.77-0.96），联合汇总接受者操作特征曲线下面积为0.
